Mersana Therapeutics reports developments as a clinical-stage biopharmaceutical company focused on antibody-drug conjugates for cancers with high unmet medical need. Its news centers on the company’s Dolasynthen and Immunosynthen ADC platforms, including Emi-Le, or emiltatug ledadotin; XMT-1660, a B7-H4-directed Dolasynthen ADC, and XMT-2056, an Immunosynthen ADC targeting a HER2 epitope.
Recurring updates include clinical data and trial disclosures for solid-tumor programs, business and financial results, material agreements, shareholder voting matters, governance items, capital-structure actions, and Nasdaq listing-related disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.